Cas:1179360-52-1 4-ethoxypyridine-2-carboximidamide,hydrochloride manufacturer & supplier

Chemical Name:4-ethoxypyridine-2-carboximidamide,hydrochloride

CAS.NO:1179360-52-1

Synonyms:4-ethoxypicolinimidamide hydrochloride

Molecular Formula:C₈H₁₂ClN₃O

Molecular Weight:201.65300

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:71.99000

Exact Mass:201.06700

LogP:2.36640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-ethoxypicolinimidamide hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-ethoxypicolinimidamide hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-ethoxypicolinimidamide hydrochloride Use and application,4-ethoxypicolinimidamide hydrochloride technical grade,usp/ep/jp grade.

Related News: Health officials said it remained unclear where he had developed the disease. 4-ethoxypyridine-2-carboximidamide,hydrochloride manufacturer Health officials said it remained unclear where he had developed the disease. 4-ethoxypyridine-2-carboximidamide,hydrochloride supplier What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. 4-ethoxypyridine-2-carboximidamide,hydrochloride vendor What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. 4-ethoxypyridine-2-carboximidamide,hydrochloride factory From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.